# Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection

> **NCT01203345** · PHASE2,PHASE3 · COMPLETED · sponsor: **NICHD Neonatal Research Network** · enrollment: 2416 (actual)

## Conditions studied

- Infant, Newborn
- Infant, Low Birth Weight
- Infant, Small for Gestational Age
- Infant, Premature
- Sepsis

## Interventions

- **DRUG:** IVIG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01203345
- **Lead sponsor:** NICHD Neonatal Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1988-01
- **Primary completion:** 1991-03
- **Final completion:** 1991-03
- **Target enrollment:** 2416 (ACTUAL)
- **Last updated:** 2019-03-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01203345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01203345, "Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01203345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*